Cosmo Pharmaceuticals has announced its intention to file for FDA approval of clascoterone 5% topical solution for androgenetic alopecia (AGA) by early 2027, following promising 12-month Phase III data demonstrating significant hair growth and a favorable safety profile for long-term use. This data supports the drug’s potential as a viable treatment for a condition that affects approximately 40% of men globally.
The Phase III program, which is the largest for any topical treatment for male AGA, involved 1,465 patients across the SCALP 1 and SCALP 2 trials conducted in the U.S. and Europe. Results indicated a 239% improvement in Target Area Hair Count (TAHC) for patients who continued treatment for a full year, reinforcing the drug’s efficacy and safety compared to vehicle controls.
CEO Giovanni Di Napoli emphasized the significance of these findings, highlighting the combination of sustained hair growth and safety as a pivotal advancement in male hair loss treatment. The positive results have bolstered investor confidence, with shares rising 6% post-announcement. As Cosmo prepares for regulatory submissions, the company is positioned to engage in advanced partnership discussions, potentially unlocking significant market opportunities in a sector projected to generate billions in sales.
Start your 7-day trial and see what the database can do →
